Drug Profile
Natalizumab - Biogen/Perrigo
Alternative Names: AN 10022; AN 100226; Antegren; Anti-alpha4 integrin monoclonal antibody - Biogen/Perrigo; BG-00002; BG-0002; BG-0002-E; TysabriLatest Information Update: 24 Nov 2023
Price :
$50
*
At a glance
- Originator Elan Corporation
- Developer Biogen; Biogen Idec; Elan Corporation; Perrigo
- Class Anti-inflammatories; Antiepileptic drugs; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Vascular disorder therapies
- Mechanism of Action Integrin alpha4beta1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Crohn's disease; Multiple sclerosis
- Phase II Graft-versus-host disease
- Discontinued Epilepsy; Multiple myeloma; Rheumatoid arthritis; Stroke
Most Recent Events
- 11 Oct 2023 Adverse events data from the phase III NOVA trial in Multiple sclerosis were presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-ACTRIMS)
- 24 Jul 2023 Biogen completes the phase-IIIb NOVA trial in Multiple Sclerosis in USA, Australia, Belgium, Canada, France, Germany, Israel, Italy, Netherlands, Spain and the UK (SC; IV) (NCT03689972)
- 22 Apr 2023 Efficacy data from clinical TOUCH programme in Multiple sclerosis presented at the 75th Annual Meeting of the American Academy of Neurology 2023 (AAN-2023)